Integra LifeSciences (IART) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $380.8M–$381M, down 0.4% year-over-year, with organic revenue down 8.6% due to supply challenges and shipping holds; adjusted EPS was $0.41, down from $0.76 last year.

• GAAP net loss for Q3 2024 was $10.7M, compared to net income of $19.5M in Q3 2023, driven by quality, operational issues, and Acclarent acquisition costs.

• Supply and production challenges, including shipping holds and Integra Skin issues, impacted results but are being addressed; compliance master plan and remediation efforts are ongoing.

• Acclarent ENT integration is progressing well, contributing to growth; strong demand for CUSA, DuraSorb, and UBM platforms.

• Mojdeh Poul appointed as next CEO, effective January 2025, following Jan De Witte’s tenure.

Financial highlights

• Adjusted EPS for Q3 2024 was $0.41, down 46% year-over-year; adjusted net income was $31.7M, down from $60.5M.

• Adjusted EBITDA margin was 16.2%, down 680bps year-over-year; adjusted EBITDA was $61.8M.

• GAAP gross margin was 52.6% (down from 57.1%); adjusted gross margin was 63.0% (down 160bps year-over-year).

• Operating cash flow for Q3 was $22.5M; free cash flow was -$7.2M; adjusted free cash flow conversion for Q3 was -22.6%.

• Net debt at September 30, 2024, was $1.54B; total liquidity was ~$1.18B, including $277M in cash and short-term investments.

Outlook and guidance

• Full-year 2024 revenue guidance is $1.609B–$1.619B (4.4%–5.0% reported growth, -1.7% to -1.0% organic); adjusted EPS guidance is $2.41–$2.49.

• Q4 2024 revenue expected at $441M–$451M (11.1%–13.6% reported, 2.0%–4.5% organic); adjusted EPS $0.81–$0.89.

• 2025 expected to show mid-single-digit organic growth over 2024, with supply disruptions already contemplated.

• Gross margin for 2024 expected to decline by 150bps; 2025 to see a further 60–80bps headwind.

• Braintree facility expected to be operational in H1 2026; Boston facility production timeline not set.